BOEHRINGER INGELHEIM


Associated tags: Human, Animal, Boehringer Ingelheim, Animal Health, Pharmaceutical industry, Health, Patient, Research

Locations: SPAIN, DELAWARE, FLORIDA, PENNSYLVANIA, UNITED STATES OF AMERICA, MASSACHUSETTS, ITALY, USA, PHILADELPHIA, EUROPEAN UNION, EU, SWITZERLAND, CANADA, LONDON, GB, TOKYO, INDIA, ENGLAND, MISSOURI, UNITED STATES, NORTH AMERICA, ILLINOIS, CONNECTICUT, INGELHEIM AM RHEIN, DE, III, II, GERMANY, EUROPE, KENYA, FRANCE, BRAZIL, UNITED KINGDOM, JAPAN, GEORGIA

Phase III Studies to Investigate Survodutide for People Living with Obesity and Overweight, with and without Diabetes, Cardiovascular Disease and Chronic Kidney Disease

Retrieved on: 
Thursday, October 5, 2023
Diabetes, Health, Pharmaceutical, Clinical Trials, Cardiology, BMI, European Association for the Study of Diabetes, Multimedia, Hypertension, Obesity, Prevalence, A1C, Ingelheim am Rhein, Disease, Overweight, Principal, Conditional sentence, EASD, Phase, Appetite, Dyslipidemia, Obstructive sleep apnea, BI, Zealand Pharma, Boehringer Ingelheim, University college, Pharmaceutical industry

Boehringer Ingelheim and Zealand Pharma A/S (NASDAQ: ZEAL) announced the initiation of three Phase III trials investigating survodutide (also known as BI 456906) for people living with overweight or obesity.

Key Points: 
  • Boehringer Ingelheim and Zealand Pharma A/S (NASDAQ: ZEAL) announced the initiation of three Phase III trials investigating survodutide (also known as BI 456906) for people living with overweight or obesity.
  • The trial design builds upon learnings from Phase II, in which people living with overweight or obesity achieved up to 19 percent weight loss.1 The Phase III trials will soon open for recruitment.
  • SYNCHRONIZE-1 will enroll people without type 2 diabetes (A1C
  • The third study, SYNCHRONIZE-CVOT, is a Phase III trial that will enroll people with overweight or obesity with cardiovascular disease, chronic kidney disease, or risk factors for cardiovascular disease.

Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss

Retrieved on: 
Monday, October 2, 2023
Technology, Medical Devices, Professional Services, Biotechnology, Health, Data Analytics, Data Management, Optical, Artificial Intelligence, Neuroprotection, Retina, Ingelheim am Rhein, Partnership, Depression, Ageing, Quality of life, Inflammation, Science, Boehringer Ingelheim, Eye, Patient, Algorithm, Diagnosis, ZEISS, AI, Paratriathlon, Automation, Pharmaceutical industry, Medical imaging, Telescopic sight

Boehringer Ingelheim and ZEISS Medical Technology announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and prevent vision loss for people with serious eye diseases.

Key Points: 
  • Boehringer Ingelheim and ZEISS Medical Technology announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and prevent vision loss for people with serious eye diseases.
  • The partnership brings together their leading expertise in ophthalmological technology, data analytics, algorithms, and the development of treatments to detect early and treat retinal diseases before irreversible loss of vision occurs.
  • * The number of people suffering from vision loss is expected to rise due to aging populations and widening health inequity gaps.
  • Unfortunately, diagnosis often occurs too late to prevent vision loss, and for many conditions, no treatment is available at all.

Adalimumab-adbm, Boehringer Ingelheim's Interchangeable biosimilar to Humira®, now available at low wholesale acquisition cost

Retrieved on: 
Monday, October 2, 2023
Interchangeability, Boehringer Ingelheim, Adalimumab, WAC, Canonical form, Acquisition, Syringe, Pharmaceutical industry

RIDGEFIELD, Conn., Oct. 2, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that Adalimumab-adbm injection, the company's interchangeable* biosimilar to Humira® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-adbm is approved to treat multiple chronic inflammatory diseases and will be priced at an 81% discount to Humira. It is also available under the brand name Cyltezo®, which launched in July 2023 and is priced at a 5% discount to Humira.

Key Points: 
  • RIDGEFIELD, Conn., Oct. 2, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that Adalimumab-adbm injection, the company's interchangeable* biosimilar to Humira® (adalimumab), is now available at a low wholesale acquisition cost (WAC).
  • Adalimumab-adbm is approved to treat multiple chronic inflammatory diseases and will be priced at an 81% discount to Humira.
  • It is also available under the brand name Cyltezo®, which launched in July 2023 and is priced at a 5% discount to Humira.
  • *Interchangeable for the conditions of use, strengths, dosage forms, and routes of administration described in its full Prescribing Information .

ZEISS and Boehringer Ingelheim join forces to develop early detection of eye diseases and prevent vision loss

Retrieved on: 
Monday, October 2, 2023
Neuroprotection, Retina, Partnership, Depression, Ageing, Ophthalmology, Quality of life, Research, Inflammation, Science, Boehringer Ingelheim, Aggregation, Eye, Patient, Algorithm, Diagnosis, ZEISS, AI, Paratriathlon, Automation, Pharmaceutical industry

JENA, Deutschland and INGELHEIM, Deutschland, Oct. 2, 2023 /PRNewswire/ -- ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

Key Points: 
  • JENA, Deutschland and INGELHEIM, Deutschland, Oct. 2, 2023 /PRNewswire/ -- ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.
  • * The number of people suffering from vision loss is rising due to aging populations and widening health inequity gaps.
  • Undiagnosed and untreated retinal diseases have a profound impact on people's lives, potentially leading to isolation, loss of independence, depression and reduced quality of life.
  • Unfortunately, diagnosis often occurs too late to prevent vision loss, and for many conditions, no treatment is available at all.

ZEISS and Boehringer Ingelheim join forces to develop early detection of eye diseases and prevent vision loss

Retrieved on: 
Monday, October 2, 2023
Neuroprotection, Retina, Partnership, Depression, Ageing, Ophthalmology, Quality of life, Research, Inflammation, Science, Boehringer Ingelheim, Aggregation, Eye, Patient, Algorithm, Diagnosis, ZEISS, AI, Paratriathlon, Automation, Pharmaceutical industry

JENA, Deutschland and INGELHEIM, Deutschland, Oct. 2, 2023 /PRNewswire/ -- ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.

Key Points: 
  • JENA, Deutschland and INGELHEIM, Deutschland, Oct. 2, 2023 /PRNewswire/ -- ZEISS Medical Technology and Boehringer Ingelheim announce today a long-term strategic collaboration to develop predictive analytics to enable early detection of eye diseases and more personalized treatments to prevent vision loss for people with serious eye diseases.
  • * The number of people suffering from vision loss is rising due to aging populations and widening health inequity gaps.
  • Undiagnosed and untreated retinal diseases have a profound impact on people's lives, potentially leading to isolation, loss of independence, depression and reduced quality of life.
  • Unfortunately, diagnosis often occurs too late to prevent vision loss, and for many conditions, no treatment is available at all.

US FDA approves Jardiance® for the treatment of adults with chronic kidney disease

Retrieved on: 
Friday, September 22, 2023
Hypersensitivity, Medical Affairs Bureau, Kidney failure, University, Chronic kidney disease, Hospital, EGFR, Glomerular filtration rate, Diabetes, Diabetic ketoacidosis, Angioedema, History, Kidney disease, Dialysis, Tablet, Boehringer Ingelheim, Transplant, Prednisone, Excipient, LLY, Polycystic kidney disease, Translational Health Science and Technology Institute, HIV disease progression rates, Patient, Risk, University of Washington Medical Center, Eli Lilly and Company, Region, Research, FDA, EMPA, CKD, III, News, NYSE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Dietary supplement, Pharmaceutical industry, Medicine

Jardiance is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease.

Key Points: 
  • Jardiance is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease.
  • "The meaningful benefits that empagliflozin demonstrated in the EMPA-KIDNEY phase III trial are welcome news for adults living with CKD in this country."
  • EMPA-KIDNEY was a large trial designed to reflect the broad range of adults with CKD with or without type 2 diabetes.
  • *Kidney disease progression: Defined as end-stage kidney disease (the initiation of maintenance dialysis or receipt of a kidney transplant), a sustained decline in estimated glomerular filtration rate (eGFR) to below 10 mL/min/1.73 m2, kidney death or a sustained decline of at least 40% in eGFR from randomization).

Boehringer Ingelheim receives SBTi validation for CO2 reduction targets

Retrieved on: 
Thursday, September 14, 2023
Health, Environment, Sustainability, Environmental Health, Climate Change, Pharmaceutical, Biotechnology, Science, Private sector, Science Based Targets initiative, Paris Agreement, MORE, Climate, LEED, Disclosure, GHG, Carbon, Targets, Certification, Strategic management, Boehringer Ingelheim, Organization, Biodiversity, EUR, Climate change, Investment, Biophysical environment, CO2, Renewable energy, Agriculture, Fornovo

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative (SBTi).

Key Points: 
  • Boehringer Ingelheim, a leading research-driven biopharmaceutical company, said on Thursday it is well on track to achieve its 2030 emission reduction targets, and that it had received approval of those targets from the Science Based Targets initiative (SBTi).
  • The SBTi drives ambitious climate action in the private sector, by enabling organizations to set science-based emissions reduction targets, while maximizing transparency, accountability, and corporate leadership through annual disclosure and progress against the targets.
  • “Driving environmental stewardship to decarbonize our business operations, both within and beyond the factory gates, has been a long-time priority at Boehringer Ingelheim,” said Felix Gutsche, Boehringer Ingelheim’s Head of Corporate Strategy & Consulting.
  • To support certified climate contribution projects that help mitigate the environmental impact of currently unavoidable emissions, Boehringer Ingelheim continues to partner with ClimateSeed.

Boehringer Ingelheim receives FDA approval for SENVELGO® (velagliflozin oral solution): the first oral liquid medication for diabetes in cats

Retrieved on: 
Monday, August 14, 2023
Online, Euthanasia, Veterinary medicine, Insulin, Food, Diabetes, University, Use, SJM, Journal of Feline Medicine and Surgery, Needle, Boehringer Ingelheim, State, Report, Animal, Risk, Trigger, Internal medicine, DOI, Diagnosis, Research, Health, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conditional sentence, Cat, Pharmaceutical industry

SENVELGO® is a once-daily liquid oral solution that cat owners can give with a small amount of food or directly into the cat's mouth.

Key Points: 
  • SENVELGO® is a once-daily liquid oral solution that cat owners can give with a small amount of food or directly into the cat's mouth.
  • Dr. Cynthia Ward, Professor Emerita of Internal Medicine at the University of Georgia and member of the U.S. Boehringer Ingelheim Diabetes Advisory Board says, "SENVELGO® oral solution is a game-changer that will revolutionize the management of feline diabetes.
  • In addition, SENVELGO® oral solution makes it simpler to successfully monitor treatment and makes time-intensive blood glucose curve monitoring redundant."
  • SENVELGO® oral solution can help pet owners and their diabetic cats continue to enjoy a normal life, despite this chronic disease."

First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas

Retrieved on: 
Tuesday, August 1, 2023
Professional Services, Health, Finance, Pharmaceutical, Biotechnology, Veterinary, Livestock, Idiopathic disease, Research and development, Idiopathic pulmonary fibrosis, Heart failure, Chronic kidney disease, Diabetes, Myocardial infarction, Executive officer, Flea, Cancer, BI, Retina, Animal Health, Coccidioides immitis, Tick, Boehringer Ingelheim, Development, EUR, Patient, Investment, PDE4B, Dog, Cat, IPF, FDA, Disease, Fine chemical, Pharmaceutical industry, Pet

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas.

Key Points: 
  • Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health expanding across its key therapy areas.
  • Overall, the company has committed to invest 25 billion EUR in Research & Development and an additional 7 billion EUR for new production technologies over the next five years.
  • Jardiance® experienced strong momentum in the first six months of 2023.
  • With the addition to existing indications in type 2 diabetes and heart failure, Jardiance® will potentially be able to help manage cardio-renal-metabolic conditions.

Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease

Retrieved on: 
Tuesday, July 25, 2023
Biotechnology, Pharmaceutical, Health, Chronic kidney disease, Hospital, Quality of life, Multimedia, SGLT2, Kidney, European Commission, Boehringer Ingelheim, Kidney disease, LLY, Risk, HR, Eli Lilly and Company, EC, CKD, NYSE, Pharmaceutical industry, EU

The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),8 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.

Key Points: 
  • The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),8 Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today.
  • Cardio-renal-metabolic conditions affect over 1 billion people worldwide.7
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230718878355/en/
    “We celebrate this significant milestone in the field of chronic kidney disease.
  • CKD is a silent killer and prevention and early detection are crucial in the general population,” said Daniel Gallego, President of European Kidney Patients’ Federation.